1. Pink Sheet

‘The Right Call:’ Australia’s PBAC Addresses ‘Unprecedented’ Backlog With Extra Meeting

 
• By Neena Brizmohun

The government’s decision for the Pharmaceutical Benefits Advisory Committee to hold an extra meeting in 2025 has been welcomed by Medicines Australia, which says that Australians already wait on average 466 days from the time a medicine is approved to when it is subsidized.

Healthcare Medicine And Pharmacy In Australia Concept Pills Vials
Australians wait longer to access drugs than people in comparable countries. (Shutterstock)

The Australian government says that the Pharmaceutical Benefits Advisory Committee will now hold an additional meeting in 2025 to address the immediate backlog of PBAC submissions from companies seeking to get their drugs subsidized under the Pharmaceutical Benefits Scheme (PBS).

Key Takeaways

The Pharmaceutical Benefits Advisory Committee will hold an additional full meeting in May 2025 to consider submissions from pharmaceutical companies that will be deferred from the March 2025 meeting because of the unprecedented number of submissions received.

The March 2025 meeting will be used to consider the submissions most likely to benefit patients and improve the standard of care in Australia

The move, announced on 6 November, follows the PBAC’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pink Sheet

More from Pricing Debate

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.